Biomarkers to monitor exacerbations in cystic fibrosis
Open Access
- 27 March 2017
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 11 (4) , 255-257
Abstract
(2017). Biomarkers to monitor exacerbations in cystic fibrosis. Expert Review of Respiratory Medicine: Vol. 11, No. 4, pp. 255-257.Keywords
This publication has 22 references indexed in Scilit:
- Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary ExacerbationsChest, 2013
- Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbationThorax, 2013
- Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trialsJournal of Cystic Fibrosis, 2011
- Sputum and serum calprotectin are useful biomarkers during CF exacerbationJournal of Cystic Fibrosis, 2010
- C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired PneumoniaThe American Journal of Medicine, 2008
- Association between Pulmonary Function and Sputum Biomarkers in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapyPediatric Pulmonology, 2005
- Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Predictive 5-Year Survivorship Model of Cystic FibrosisAmerican Journal of Epidemiology, 2001
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994